FRINK Linked Data Fragments server

Matches in SemOpenAlex for { <https://semopenalex.org/work/W2114875729> ?p ?o ?g. }

• W2114875729 abstract "Metastatic castration-resistant prostate cancer (mCRPC) and its treatment significantly affect health-related quality of life (HRQOL). Our objectives were to evaluate and compare patient-reported outcome (PRO) claims granted by the Food and Drug Administration (FDA) and European Medicines Agency (EMA) for 5 recently approved mCRPC treatments and to examine key characteristics, development, and measurement properties of the PRO measures supporting these claims against current regulatory standards. Five products approved for treatment of mCRPC by the FDA and the EMA (2010–2013) were examined: enzalutamide, abiraterone, sipuleucel-T, cabazitaxel, and radium Ra 223 dichloride. United States (US) drug approval packages and European Public Assessment Reports were reviewed. PRO claims in the US labels and European Summaries of Product Characteristics and supporting measures were identified. For PRO measures supporting claims, a targeted literature review was conducted to identify information on key characteristics and measurement properties; this information was compared against FDA PRO guidance criteria. Nine PRO “claims” were granted across 4 of 5 products reviewed. The EMA granted more claims (7 claims—4 for pain, 3 for HRQOL) than the FDA (2 claims, both for pain). The Brief Pain Inventory–Short Form (BPI-SF) worst pain item supported most pain claims and was the only measure supporting US claims. EMA pain claims were supported by BPI-SF worst pain (n = 2) and average pain (n = 1) items and the McGill Pain Questionnaire Present Pain Intensity component (n = 1). EMA HRQOL claims were supported by the Functional Assessment of Cancer Therapy–Prostate Module (n = 2) and the EuroQol 5 Dimensions with visual analogue scale (n = 1). Pain and prostate cancer–specific HRQOL measures supporting claims met US regulatory standards for construct validity, reliability, and responsiveness; these properties were strongest for the BPI-SF worst pain item. Only the BPI-SF worst pain item has documented content validity in mCRPC. PRO label claims were commonly granted across the mCRPC products reviewed. Among the measures reviewed, only the BPI-SF worst pain item supported US label claims. The BPI-SF worst pain item is recommended for pain assessment for the evaluation of new mCRPC treatments." @default.
• W2114875729 created "2016-06-24" @default.
• W2114875729 creator A5013552023 @default.
• W2114875729 creator A5027918007 @default.
• W2114875729 creator A5027957946 @default.
• W2114875729 creator A5033439540 @default.
• W2114875729 creator A5077009112 @default.
• W2114875729 date "2014-07-04" @default.
• W2114875729 modified "2023-10-13" @default.
• W2114875729 title "Patient-reported outcome labeling claims and measurement approach for metastatic castration-resistant prostate cancer treatments in the United States and European Union" @default.
• W2114875729 cites W1553764206 @default.
• W2114875729 cites W1759608414 @default.
• W2114875729 cites W1993396608 @default.
• W2114875729 cites W2000159285 @default.
• W2114875729 cites W2004909463 @default.
• W2114875729 cites W2011864602 @default.
• W2114875729 cites W2011964270 @default.
• W2114875729 cites W2019532333 @default.
• W2114875729 cites W2021837603 @default.
• W2114875729 cites W2029087193 @default.
• W2114875729 cites W2054346664 @default.
• W2114875729 cites W2058062171 @default.
• W2114875729 cites W2065142831 @default.
• W2114875729 cites W2080439368 @default.
• W2114875729 cites W2084518320 @default.
• W2114875729 cites W2093632144 @default.
• W2114875729 cites W2097566830 @default.
• W2114875729 cites W2113746964 @default.
• W2114875729 cites W2120292596 @default.
• W2114875729 cites W2123526148 @default.
• W2114875729 cites W2127307826 @default.
• W2114875729 cites W2128373662 @default.
• W2114875729 cites W2138809580 @default.
• W2114875729 cites W2148643283 @default.
• W2114875729 cites W2153148011 @default.
• W2114875729 doi "https://doi.org/10.1186/s12955-014-0104-5" @default.
• W2114875729 hasPubMedCentralId "https://www.ncbi.nlm.nih.gov/pmc/articles/4104468" @default.
• W2114875729 hasPubMedId "https://pubmed.ncbi.nlm.nih.gov/24989428" @default.
• W2114875729 hasPublicationYear "2014" @default.
• W2114875729 type Work @default.
• W2114875729 sameAs 2114875729 @default.
• W2114875729 citedByCount "26" @default.
• W2114875729 countsByYear W21148757292014 @default.
• W2114875729 countsByYear W21148757292015 @default.
• W2114875729 countsByYear W21148757292016 @default.
• W2114875729 countsByYear W21148757292017 @default.
• W2114875729 countsByYear W21148757292018 @default.
• W2114875729 countsByYear W21148757292019 @default.
• W2114875729 countsByYear W21148757292020 @default.
• W2114875729 countsByYear W21148757292021 @default.
• W2114875729 countsByYear W21148757292022 @default.
• W2114875729 countsByYear W21148757292023 @default.
• W2114875729 crossrefType "journal-article" @default.
• W2114875729 hasAuthorship W2114875729A5013552023 @default.
• W2114875729 hasAuthorship W2114875729A5027918007 @default.
• W2114875729 hasAuthorship W2114875729A5027957946 @default.
• W2114875729 hasAuthorship W2114875729A5033439540 @default.
• W2114875729 hasAuthorship W2114875729A5077009112 @default.
• W2114875729 hasBestOaLocation W21148757291 @default.
• W2114875729 hasConcept C105639569 @default.
• W2114875729 hasConcept C121608353 @default.
• W2114875729 hasConcept C126322002 @default.
• W2114875729 hasConcept C144133560 @default.
• W2114875729 hasConcept C159110408 @default.
• W2114875729 hasConcept C1862650 @default.
• W2114875729 hasConcept C2776551883 @default.
• W2114875729 hasConcept C2777899217 @default.
• W2114875729 hasConcept C2778282284 @default.
• W2114875729 hasConcept C2778971682 @default.
• W2114875729 hasConcept C2779517570 @default.
• W2114875729 hasConcept C2779951463 @default.
• W2114875729 hasConcept C2780052408 @default.
• W2114875729 hasConcept C2780192828 @default.
• W2114875729 hasConcept C2781118164 @default.
• W2114875729 hasConcept C2910001868 @default.
• W2114875729 hasConcept C2983098980 @default.
• W2114875729 hasConcept C512399662 @default.
• W2114875729 hasConcept C61367390 @default.
• W2114875729 hasConcept C71924100 @default.
• W2114875729 hasConceptScore W2114875729C105639569 @default.
• W2114875729 hasConceptScore W2114875729C121608353 @default.
• W2114875729 hasConceptScore W2114875729C126322002 @default.
• W2114875729 hasConceptScore W2114875729C144133560 @default.
• W2114875729 hasConceptScore W2114875729C159110408 @default.
• W2114875729 hasConceptScore W2114875729C1862650 @default.
• W2114875729 hasConceptScore W2114875729C2776551883 @default.
• W2114875729 hasConceptScore W2114875729C2777899217 @default.
• W2114875729 hasConceptScore W2114875729C2778282284 @default.
• W2114875729 hasConceptScore W2114875729C2778971682 @default.
• W2114875729 hasConceptScore W2114875729C2779517570 @default.
• W2114875729 hasConceptScore W2114875729C2779951463 @default.
• W2114875729 hasConceptScore W2114875729C2780052408 @default.
• W2114875729 hasConceptScore W2114875729C2780192828 @default.
• W2114875729 hasConceptScore W2114875729C2781118164 @default.
• W2114875729 hasConceptScore W2114875729C2910001868 @default.
• W2114875729 hasConceptScore W2114875729C2983098980 @default.
• W2114875729 hasConceptScore W2114875729C512399662 @default.
• W2114875729 hasConceptScore W2114875729C61367390 @default.
• W2114875729 hasConceptScore W2114875729C71924100 @default.
• W2114875729 hasIssue "1" @default.

• next